COMMUNIQUÉS West-GlobeNewswire

Noom Health’s SmartRx Program on Track to Cut Employer’s GLP-1 Spend by Nearly 80%
23/04/2026
Early data from first participating employer show that Smart Rx can save organizations millions by bypassing traditional PBMs to deliver brand-name GLP-1 medications NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Noom [...]
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
23/04/2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet [...]
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
23/04/2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant tumor volume [...]
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
23/04/2026
Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present [...]
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
23/04/2026
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage [...]
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
23/04/2026
Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side [...]
SS Innovations Unveils Cutting-Edge Surgical Robotic Technologies at SMRSC 2026
23/04/2026
Innovations under development by Company include the SSi Vimana Aero, SSi Avtara and SSi Operion FORT LAUDERDALE, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS [...]
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
23/04/2026
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter [...]
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
23/04/2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, [...]
Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
23/04/2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in- [...]
Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call
23/04/2026
ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 14 [...]
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
23/04/2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
23/04/2026
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years with type 2 diabetes, addressing a significant unmet need. The trial demonstrated a statistically [...]
Orion Group Interim report January–March 2026
23/04/2026
ORION CORPORATION INTERIM REPORT 1–3/2026 23 APRIL 2026 at 12:00 EEST Orion Group Interim report January–March 2026 January–March 2026 Highlights Net sales totalled EUR 417.7 (January–March 2025: 354.6) million [...]
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
23/04/2026
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing [...]
ENA Respiratory Appoints Melissa Faris to Board
23/04/2026
MELBOURNE, Australia, April 23, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé
23/04/2026
Nomme la professeure Susana Banerjee, éminente oncologue du Royal Marsden, en tant que chercheuse principale CAMBRIDGE, Royaume-Uni et MONTRÉAL, 23 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société biotechnologique [...]
Press Release: Q1 2026: double-digit sales and business EPS growth
23/04/2026
Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER 1 and business earnings per share (EPS) 2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 [...]
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
23/04/2026
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno [...]

Pages